Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone...
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that...
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD)...
Persephone Persephone - A First-Of-Its-Kind Synbiotic Newly released data shows that nine in ten babies lack critical gut microbes needed...
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small...
NEW YORK and PARIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies, today presented new...
De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET...
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today...
Avidion brings clarity to immune drug-tumor interactions, helping scientists identify better cell therapy candidates, understand mechanisms, and advance with confidence....
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in...
PISCATAWAY, N.J., Sept. 8, 2025 /PRNewswire/ -- Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future...
HOLON, ISRAEL, Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a...
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for...
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September...
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK...
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in...
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of...
Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology...
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and...